CN-114487443-B - New use of sCD73 as immune reconstruction condition marker for predicting HIV/AIDS patient after antiviral treatment

Abstract

The invention provides a novel application of soluble CD73 (sCD 73) as a marker for predicting immune reconstruction condition of an HIV/AIDS patient after antiviral treatment, belonging to the technical field of biological medicine. The sCD73 can be used for predicting the reconstruction condition of the immune system of an HIV/AIDS patient after antiviral treatment, and has the advantages of rapid and accurate detection, low cost and the like, and has wide application prospect.

Inventors

• KONG YAXIAN
• ZHAO HONGXIN
• WANG XINLI
• DU JUAN

Assignees

• 首都医科大学附属北京地坛医院

Dates

Publication Date

20260512

Application Date

20220307

Claims (3)

1. 1. Use of a reagent capable of detecting the concentration of sCD73 in blood plasma for the preparation of a product for predicting or assisting in predicting whether or not the immune reconstitution of an HIV/AIDS patient after antiviral treatment is poor, characterized in that the concentration of sCD73 in blood plasma isolated from the peripheral blood of the patient to be tested is detected, the detected value of the concentration of sCD73 is compared with a reference value, which is the Cut-off value of the concentration of sCD73 obtained from the HIV/AIDS patient population, in particular 4.111ng/ml, and when the detected value of the concentration of sCD73 is higher than the reference value, the patient to be tested is judged to be poor in the immune reconstitution after antiviral treatment.
2. 2. The use according to claim 1, wherein the product is a kit, an antibody chip, an antibody probe or a detector.
3. 3. The use according to claim 2, wherein the kit comprises reagents for obtaining peripheral blood from the patient, and/or reagents for separating plasma.

Description

New use of sCD73 as immune reconstruction condition marker for predicting HIV/AIDS patient after antiviral treatment Technical Field The invention relates to the technical field of biological medicine, in particular to a novel application of sCD73 as a marker for predicting immune reconstruction condition of an HIV/AIDS patient after antiviral treatment. Background The morbidity and mortality of HIV/AIDS patients drops significantly with the widespread use of antiviral therapies that can continuously inhibit HIV virus replication and gradually restore CD4T cell counts. However, although viral replication can be completely inhibited after antiviral treatment, CD4T cell counts in 10% -40% of patients are not restored to normal levels. Such patients are known as poor immune reconstitution and they often exhibit a deficit in the immune system. The risk of AIDS-related and non-AIDS related events and death is higher in patients with poor reconstitution compared to patients with good reconstitution of the immunity. To date, many therapies for immune dysreconstruction are under investigation, but no effective therapies have yet emerged, as the complex mechanisms of immune dysreconstruction have not yet been elucidated. Early identification/prediction of patients who may develop poor immune reconstruction, periodic monitoring and timely adoption of adjuvant therapy is critical to improving clinical outcome. Thus, there is a need to further explore a scientific and practical way to guide clinicians in early recognition/prediction of which patients' immune systems are not easily restored. Previous studies have discussed parameters for predicting the immune reconstitution status of patients after antiviral treatment. The predictors currently in common use include baseline CD4 counts and CD4/CD8 ratios. However, in hospitals where resources are limited, relatively expensive flow cytometers are not widely used, and predicting immune reconstitution by the number or proportion of immune cells presents a challenge. In addition, only routine detection of cell counts will ignore their function of cells and other information of the whole immune environment. Studies have shown that after antiviral treatment, viral load and CD4 counts can return to normal in some patients, but their immune system remains overactive and such people are more prone to developing as immunocompromised patients. Cell counts do not completely accurately predict the reconstitution of the patient's immune system function, and therefore, there is a need to explore and develop biomarkers for predicting the reconstitution of the immune of HIV/AIDS patients, thereby enabling rapid, convenient and accurate prediction of the reconstitution of the immune. Disclosure of Invention First, the technical problem to be solved In view of the above-mentioned shortcomings and drawbacks of the prior art, the present invention provides a marker for early prediction or assessment of post-antiviral treatment immune reconstitution status of HIV/AIDS patients, and a product for prediction or assessment of post-antiviral treatment immune reconstitution status of HIV/AIDS patients using the same, so as to provide monitoring and timely intervention for patients who may have poor immune reconstitution. (II) technical scheme In order to achieve the above purpose, the main technical scheme adopted by the invention comprises the following steps: In a first aspect, the present invention provides a novel use of sCD73 as a marker for predicting the post-antiviral treatment immune reconstitution status of HIV/AIDS patients. In a second aspect, the invention provides the use of an antibody specifically recognizing CD73 for the preparation of a product for predicting or aiding in predicting whether an immune reconstitution of an HIV/AIDS patient after antiviral treatment is poor. Preferably, the product is a detection reagent, a kit, an antibody chip, an antibody probe or a detector. Preferably, the kit comprises an antibody specifically recognizing CD73, a biotin-labeled CD73 antibody and an avidin-biotin-peroxidase complex. Preferably, the kit further comprises reagents for obtaining peripheral blood from the patient and/or reagents for separating plasma. Preferably, the plasma is plasma isolated from peripheral blood. In a third aspect, the invention provides a product for predicting whether an immune reconstitution of an HIV/AIDS patient after antiviral treatment is poor, said product being capable of detecting the concentration of sCD73 in plasma. Preferably, the product is a detection reagent, a kit, an antibody chip, an antibody probe or a detector. Preferably, the plasma is peripheral blood. Preferably, the detection reagent is an ELISA kit for specifically binding sCD73, and the kit can detect the concentration of sCD73 protein in blood plasma by specifically binding sCD73 in blood plasma. For example, the sCD73 ELISA kit used in the examples was purchased from Abcam (ab 213761)